TG Therapeutics, Inc. (NASDAQ:TGTX) shares are moving higher on Friday.
What To Know:
TG Therapeutics launched Briumvi, a drug for the treatment of relapsing forms of MS, in the first quarter of 2023. The company reported first quarter product revenue from Briumvi alone at $7.8 million and projected continued revenue growth for the drug.
According to data from Benzinga Pro, TGTX has considerable short interest with 18.59% of available shares currently being sold short. TGTX stock is also receiving attention from retail investors with the stock currently listed as a top trending ticker on StockTwits and Yahoo!.
Related News: Prestige Wealth Management (PWM) Stock Is Ripping Higher: What’s Going On?
TGTX Price Action: According to Benzinga Pro, TG Therapeutics shares are trading 11% higher at $25.58 at the time of publication.
Image: akirEVarga from Pixabay
